ETH spin-off Sleepiz has already launched its first product, Sleepiz One, a small device that is placed next to the patient’s bed. Completely contactless, the Sleepiz One measures human vital signs with medical accuracy. Currently, the first customers in Switzerland and India use the Sleepiz One for sleep apnea screenings, a disorder that affects 1 billion people worldwide but of which only 20% are diagnosed.

The newly raised capital will support Sleepiz expansion of its current offering. Chronic respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD), as well as recently COVID-19, are one of the leading causes of death worldwide. With continuous remote monitoring and timely interventions, these deaths can be prevented. The next generation of Sleepiz One, Sleepiz One Connect, integrates additional measurements and an enhanced telehealth platform for more actionable insights. By remotely monitoring patient’s respiration rate and patterns together with blood oxygen measurements, the Sleepiz telehealth platform helps caregivers identify and act upon patient deterioration before it is too late. The Sleepiz telehealth CARE team, equipped with professionally trained specialists, adds another safety layer by keeping an eye on the patients 24/7.

“Sleepiz pursues a compelling vision of making vital sign monitoring touchless, which is a paradigm shift in the industry and paves the way for a new future of healthcare”, said Steffen Wagner, Co-CEO of Verve Ventures.

Sleepiz has already successfully completed its clinical investigations with leading clinics and key opinion leaders in the DACH market. With these early successes, Sleepiz aims to expand its core markets and enter the rest of Europe and the US. Additionally, the raised capital will enable Sleepiz to classify as a Class IIa medical device under the European medical device regulation.

So far, Sleepiz has received non-dilutive funding of CHF 3 million through Innosuisse, Eurostar, Horizon 2020, EIT Health, Volkswirtschaftsstiftung, DeVigier, and several other awards. In just over three years, the ETH spin-off has grown to a team of more than 50 people including PhDs in engineering, data modelling and signal processing, as well as business and healthcare professionals. Headquartered in Zürich, Switzerland, Sleepiz AG also has its own subsidiary in Pune, India. The company collaborates closely with leading clinics in Switzerland and Europe.